Zinc and Male Fertility: What Did the Large FAZST Trial Show?

Zinc is a cofactor for over 300 enzymes in the body and takes part in the enzymatic pathways of testosterone production in the testes, which we describe in more detail in our knowledge-base entry on zinc. It's also a structural component of the sperm cell itself — present at high concentration in the head and tail, where it likely plays a role in stabilizing sperm chromatin and protecting against oxidative stress. The hypothesis that its supplementation could improve semen quality wasn't unreasonable — it had solid biochemical grounding.

It's precisely this biological plausibility that made zinc — usually paired with folic acid, which supports DNA synthesis and the cell division essential to spermatogenesis — one of the most heavily marketed ingredients in "male fertility" supplements for years. The male factor accounts for roughly half of all cases of couple infertility, which we cover in our entry on male fertility, and the supplement market is happy to meet that demand with promises of improved semen parameters.

The problem is that for years these promises rested mainly on small, short observational and pilot studies — exactly the kind of evidence that sounds convincing in an ad but rarely survives confrontation with a large, rigorously designed clinical trial. That confrontation happened in 2020, and its result deserves an honest discussion — not as an attack on zinc supplementation as such, but as an update to what's actually known about its effect on fertility.

This trial was designed specifically to answer that one question — unlike many earlier, smaller studies, where the effect on fertility was often a secondary outcome or a conclusion drawn indirectly from an improvement in a single lab parameter. Here, the primary endpoint was a hard, clinical outcome — a live birth — not just a sperm count per milliliter of semen.

This doesn't mean the smaller, earlier studies were poorly done or dishonest — small samples are simply far more susceptible to random result fluctuation, and methodological differences (a different dose, a different population, lack of blinding) easily lead to false-positive conclusions. FAZST doesn't "invalidate" those studies in the sense of nullifying them — it simply provides much stronger evidence that should take precedence when formulating practical recommendations.

There were also more frequent gastrointestinal adverse events in the supplementation group: abdominal discomfort (6% versus 3% in placebo), nausea (4% versus 2%), and vomiting (3% versus 1%). None of these effects is dangerous on its own, but combined with the absence of any demonstrated benefit, they shift the risk-benefit balance of high-dose "just in case" supplementation — 30 mg of elemental zinc daily is a dose clearly above the standard recommended daily intake (8-11 mg), used here without a confirmed deficiency.

It's worth stressing that this distinction applies specifically to high-dose zinc and folic acid supplementation in men without a confirmed deficiency. Our knowledge-base entry on zinc describes a separate, well-documented situation: in men with a real, blood-test-confirmed zinc deficiency, supplementation corrects that deficiency and can normalize testosterone levels. FAZST did not test that situation — it tested supplementation regardless of baseline zinc status, in a population of couples already being treated for infertility.

Despite its large sample and solid design, FAZST has its limits. Participants were men from couples already being treated for infertility at specialized clinics in the US — the result doesn't necessarily generalize directly to all men, including those without diagnosed infertility or those from populations with a different baseline zinc and folic acid status (e.g. in countries with more common dietary deficiencies). The trial evaluated one specific dose and one combination (zinc + folic acid) on one dosing schedule over 6 months — this doesn't theoretically rule out a different response at a different dose, over a longer period, or in a subgroup of men with a low baseline zinc level, though the trial provided no evidence of such an effect in the population studied.

The hypothesis that zinc could support male fertility had solid biochemical grounding, and earlier small studies fueled enough hope that zinc-and-folic-acid supplements became one of the most commonly recommended "first steps" for couples trying to conceive. The largest clinical trial on the subject to date, however, showed that this specific intervention — at this dose, in this population — doesn't work, and along the way carries a signal of possible harm. That's exactly the kind of result that deserves honest coverage, even when it's less catchy than a promise of improvement.